false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP11.03. Clinical Impact of Immune Checkpoint Inhi ...
EP11.03. Clinical Impact of Immune Checkpoint Inhibitors Following Platinum Chemotherapy in Advanced or Metastatic Non-small Cell Lung Cancer Patients - PDF(Abstract)
Back to course
Pdf Summary
This study aimed to analyze the impact of immune checkpoint inhibitors (ICIs) on both medical expenses and prognosis of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had received platinum chemotherapy. The study utilized data from the entire population of the Korean National Health Insurance Service. The effect of ICIs on overall mortality, progression-free survival, and medical expenditure was evaluated using interrupted time series analysis.<br /><br />The final study population consisted of 3,806 patients in the ICI group and 4,812 patients in the non-ICI group. The results showed that ICI treatment was a significant negative risk factor for overall survival, indicating that the use of ICIs following platinum chemotherapy improved the overall survival rate among advanced NSCLC patients. Additionally, ICI-treated patients were more likely to experience disease progression.<br /><br />The study also found that the introduction of ICIs led to an increasing trend in both total and cancer-related medical expenses per capita. This suggests that the use of ICIs is associated with an increase in individual medical expenses.<br /><br />In conclusion, the study highlights the clinical impact of ICIs following platinum chemotherapy in advanced NSCLC patients. While ICIs improve overall survival, the increase in medical expenses necessitates further research to identify patients for whom ICI treatment may be more effective. This research could help optimize treatment strategies and alleviate the financial burden on patients.
Asset Subtitle
Sang Chul Lee
Meta Tag
Speaker
Sang Chul Lee
Topic
Metastatic NSCLC: Immunotherapy - Retrospective
Keywords
immune checkpoint inhibitors
medical expenses
prognosis
advanced non-small cell lung cancer
metastatic non-small cell lung cancer
platinum chemotherapy
Korean National Health Insurance Service
overall mortality
progression-free survival
interrupted time series analysis
×
Please select your language
1
English